cytochrome P450 family 2 subfamily T member 3, pseudogeneGenealiases: []
Q-omics provides the consensus-scored CYP2T3P profile across patient tissues and cancer cell-line models. CYP2T3P expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CYP2T3P is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, CYP2T3P RNA expression shows 11,668 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight ACC, COAD, and ESCA as cancer lineages where CYP2T3P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYP2T3P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYP2T3P survival associations across molecular data types. CYP2T3P RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYP2T3P RNA expression–survival associations across cancer types. High CYP2T3P expression shows unfavorable associations in COAD, KIRC and KIRP, but favorable associations in ACC, MESO and STAD. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify ACC as the clearest survival context for CYP2T3P RNA expression.
This table summarizes CYP2T3P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for CYP2T3P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYP2T3P shows lower tumor expression in KICH and higher tumor expression in COAD, BRCA, STAD, READ and PAAD. The COAD box plot shows higher CYP2T3P RNA expression in tumor versus normal tissue (log2 FC = +0.385, t-test p = .005).
This table shows molecular features associated with CYP2T3P in patient tissues and cancer cell lines. In patient samples, CYP2T3P shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
